Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib and Decitabine in Myelofibrosis and MPN/MDS
NCT02564536Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of pacritinib in myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML) and 2 more, sponsored by Washington University School of Medicine. Planned start Jun 2017; status: withdrawn.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)chronic myelomonocytic leukemia (CMML)juvenile myelomonocytic leukemia (JMML)Atypical chronic myeloid leukemia (aCML)Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome
Beyond the preview
Go deeper on NCT02564536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564536.